Identification

Name
Diflunisal
Accession Number
DB00861  (APRD00922, DB06895)
Type
Small Molecule
Groups
Approved
Description

Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.

Structure
Thumb
Synonyms
  • 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid
  • 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid
  • 5-(2,4-Difluorophenyl)salicylic acid
  • Diflunisal
  • Diflunisalum
External IDs
MK 647
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DiflunisalTablet500 mgOralAa Pharma Inc1993-12-31Not applicableCanada
DiflunisalTablet250 mgOralAa Pharma Inc1993-12-31Not applicableCanada
Diflunisal-250 - Tab 250mgTablet250 mgOralPro Doc Limitee1995-12-312000-07-31Canada
Diflunisal-500 - Tab 500mgTablet500 mgOralPro Doc Limitee1995-12-312000-07-31Canada
Dolobid Tab 250mgTablet250 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-311998-08-14Canada
Dolobid Tab 500mgTablet500 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-312000-08-03Canada
Novo-diflunisalTablet250 mgOralTeva1993-12-31Not applicableCanada
Novo-diflunisalTablet500 mgOralTeva1993-12-31Not applicableCanada
Nu-diflunisal Tab 250mgTablet250 mgOralNu Pharm Inc1994-12-312012-09-04Canada
Nu-diflunisal Tab 500mgTablet500 mgOralNu Pharm Inc1994-12-312012-09-04Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DiflunisalTablet, film coated500 mg/1OralA S Medication Solutions1992-11-012017-06-20Us
DiflunisalTablet500 mg/1OralCadila Pharnmaceuticals2017-09-14Not applicableUs
DiflunisalTablet, film coated500 mg/1OralRising Pharmaceuticals2012-05-01Not applicableUs
DiflunisalTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.1992-11-01Not applicableUs
DiflunisalTablet, film coated500 mg/1OralPhysicians Total Care, Inc.2009-07-21Not applicableUs
DiflunisalTablet, film coated500 mg/1OralA S Medication Solutions1992-11-012017-06-20Us
DiflunisalTablet, film coated500 mg/1OralA S Medication Solutions2012-05-012017-06-20Us
DiflunisalTablet500 mg/1OralZydus Pharmaceuticals Usa, Inc.2017-09-14Not applicableUs
DiflunisalTablet, film coated500 mg/1OralTeva1992-11-01Not applicableUs00093 0755 06 nlmimage10 752b3ae9
DiflunisalTablet, film coated500 mg/1OralCarilion Materials Management1992-11-01Not applicableUs
International/Other Brands
Anton (Everest) / Dolobid (Merck)
Categories
UNII
7C546U4DEN
CAS number
22494-42-4
Weight
Average: 250.1976
Monoisotopic: 250.044150532
Chemical Formula
C13H8F2O3
InChI Key
HUPFGZXOMWLGNK-UHFFFAOYSA-N
InChI
InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
IUPAC Name
5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
SMILES
OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1

Pharmacology

Indication

For symptomatic treatment of mild to moderate pain accompanied by inflammation (e.g. musculoskeletal trauma, post-dental extraction, post-episiotomy), osteoarthritis, and rheumatoid arthritis.

Structured Indications
Pharmacodynamics

Diflunisal is a nonsteroidal drug with analgesic, anti-inflammatory and antipyretic properties. It is a peripherally-acting non-narcotic analgesic drug. Habituation, tolerance and addiction have not been reported. Diflunisal is a difluorophenyl derivative of salicylic acid. Chemically, diflunisal differs from aspirin (acetylsalicylic acid) in two respects. The first of these two is the presence of a difluorophenyl substituent at carbon 1. The second difference is the removal of the 0-acetyl group from the carbon 4 position. Diflunisal is not metabolized to salicylic acid, and the fluorine atoms are not displaced from the difluorophenyl ring structure.

Mechanism of action

The precise mechanism of the analgesic and anti-inflammatory actions of diflunisal is not known. Diflunisal is a prostaglandin synthetase inhibitor. In animals, prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain. Since prostaglandins are known to be among the mediators of pain and inflammation, the mode of action of diflunisal may be due to a decrease of prostaglandins in peripheral tissues.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
Absorption

Rapidly and completely absorbed following oral administration, with a bioavailability of 80-90%. Peak plasma concentrations are achieved 2 - 3 hours following oral administration.

Volume of distribution
Not Available
Protein binding

At least 98 to 99% of diflunisal in plasma is bound to proteins.

Metabolism

Hepatic, primarily via glucuronide conjugation (90% of administered dose).

Route of elimination

The drug is excreted in the urine as two soluble glucuronide conjugates accounting for about 90% of the administered dose. Little or no diflunisal is excreted in the feces.

Half life

8 to 12 hours

Clearance
Not Available
Toxicity

Oral LD50 in rat, mouse, and rabbit is 392 mg/kg, 439 mg/kg, and 603 mg/kg, respectively. Symptoms of overdose include drowsiness, nausea, vomiting, diarrhea, hyperventilation, tachycardia, sweating, tinnitus, disorientation, stupor, and coma. The lowest dose without the presence of other medicines which caused death was 15 grams.

Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of diflunisal. Short-term use does not appear to be associated with increased cardiovascular risk (except when used immediately following coronary artery bypass graft (CABG) surgery). Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Severe hepatic reactions, including cholestasis and/or jaundice, have been reported. May cause rash or hypersensitivity syndrome.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Diflunisal Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Diflunisal is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Diflunisal is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Diflunisal.Approved
AcarboseDiflunisal may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololDiflunisal may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Aceclofenac.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Acemetacin.Approved
AcenocoumarolDiflunisal may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Diflunisal.Approved, Vet Approved
AclarubicinDiflunisal may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Diflunisal.Approved
AlbiglutideDiflunisal may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alendronic acid.Approved
AliskirenDiflunisal may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alminoprofen.Experimental
AlogliptinDiflunisal may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Aloxiprin.Experimental
AlprenololDiflunisal may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Diflunisal.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alteplase.Approved
ALX-0081The risk or severity of adverse effects can be increased when Diflunisal is combined with ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Amcinonide.Approved
AmikacinDiflunisal may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideDiflunisal may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Diflunisal.Approved
Ammonium chlorideThe serum concentration of Diflunisal can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
AmrubicinDiflunisal may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Diflunisal.Approved
AncrodDiflunisal may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Diflunisal is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Diflunisal is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Anisodamine.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Anistreplase.Approved
annamycinDiflunisal may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Antipyrine.Approved
Antithrombin III humanDiflunisal may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanDiflunisal may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Diflunisal is combined with Apocynin.Investigational
ApramycinDiflunisal may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Diflunisal is combined with Apremilast.Approved, Investigational
ArbekacinDiflunisal may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinDiflunisal may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Diflunisal.Approved, Investigational
ArotinololDiflunisal may decrease the antihypertensive activities of Arotinolol.Approved
AstaxanthinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Atamestane.Investigational
AtenololDiflunisal may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Diflunisal.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Diflunisal.Approved
BalsalazideDiflunisal may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Batroxobin.Experimental
BecaplerminDiflunisal may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololDiflunisal may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinDiflunisal may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bemiparin.Approved
BenazeprilDiflunisal may decrease the antihypertensive activities of Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diflunisal.Approved
BenorilateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Benoxaprofen.Withdrawn
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Diflunisal.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Betamethasone.Approved, Vet Approved
BetaxololDiflunisal may decrease the antihypertensive activities of Betaxolol.Approved
BevantololDiflunisal may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Diflunisal.Approved, Investigational
BisoprololDiflunisal may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinDiflunisal may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololDiflunisal may decrease the antihypertensive activities of Bopindolol.Approved
BrinaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Brinzolamide.Approved
BromfenacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bromfenac.Approved
BromocriptineDiflunisal may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bucillamine.Investigational
BucindololDiflunisal may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bufexamac.Experimental
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Diflunisal.Experimental
BufuralolDiflunisal may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bumadizone.Experimental
BumetanideDiflunisal may decrease the diuretic activities of Bumetanide.Approved
BupranololDiflunisal may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Diflunisal.Investigational
CanagliflozinDiflunisal may increase the hypoglycemic activities of Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Diflunisal.Approved
CandoxatrilDiflunisal may decrease the antihypertensive activities of Candoxatril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Diflunisal.Approved
CaptoprilDiflunisal may decrease the antihypertensive activities of Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Diflunisal is combined with Carbaspirin calcium.Experimental
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Diflunisal.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Diflunisal.Approved, Vet Approved, Withdrawn
CarteololDiflunisal may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolDiflunisal may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Castanospermine.Experimental
CeliprololDiflunisal may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinDiflunisal may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Diflunisal.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diflunisal.Approved, Vet Approved
ChlorpropamideDiflunisal may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Diflunisal.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ciclesonide.Approved, Investigational
CilazaprilDiflunisal may decrease the antihypertensive activities of Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Diflunisal.Approved
CinoxacinDiflunisal may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
Citric AcidDiflunisal may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clonixin.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Diflunisal.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Diflunisal.Vet Approved
CloranololDiflunisal may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Diflunisal.Experimental
ClorindioneDiflunisal may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Diflunisal is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Diflunisal.Experimental
CyclosporineDiflunisal may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Diflunisal is combined with D-Limonene.Investigational
Dabigatran etexilateDiflunisal may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinDiflunisal may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDiflunisal may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinDiflunisal may increase the hypoglycemic activities of Dapagliflozin.Approved
DarexabanDiflunisal may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinDiflunisal may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Diflunisal is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Diflunisal.Approved, Investigational
DelaprilDiflunisal may decrease the antihypertensive activities of Delapril.Experimental
dersalazineDiflunisal may increase the anticoagulant activities of dersalazine.Investigational
DesirudinDiflunisal may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexketoprofen.Approved
DextranDiflunisal may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Diflunisal may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Diflunisal may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Diflunisal may increase the anticoagulant activities of Dextran 75.Approved
DibekacinDiflunisal may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Diflunisal.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Diclofenamide.Approved
DicoumarolDiflunisal may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Diflorasone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Diflunisal.Approved
DihydrostreptomycinDiflunisal may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Diflunisal.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Diflunisal.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Diflunisal.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Diflunisal.Approved
DiphenadioneDiflunisal may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Diflunisal.Approved
DisopyramideDiflunisal may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dorzolamide.Approved
DoxorubicinDiflunisal may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneDiflunisal may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Diflunisal is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Droxicam.Approved
DulaglutideDiflunisal may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Diflunisal is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Diflunisal is combined with E-6201.Investigational
Edetic AcidDiflunisal may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanDiflunisal may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinDiflunisal may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilDiflunisal may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatDiflunisal may decrease the antihypertensive activities of Enalaprilat.Approved
EnoxacinDiflunisal may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinDiflunisal may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Diflunisal.Experimental
EpanololDiflunisal may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Diflunisal.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Diflunisal is combined with Epirizole.Approved
EpirubicinDiflunisal may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneDiflunisal may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Diflunisal.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Diflunisal.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Diflunisal.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diflunisal.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Diflunisal.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Diflunisal is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Equilin.Approved
EsmololDiflunisal may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Estrone sulfate.Approved
Etacrynic acidDiflunisal may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Diflunisal.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ethenzamide.Experimental
EthoxzolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateDiflunisal may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etofenamate.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Diflunisal is combined with Evening primrose oil.Approved
ExenatideDiflunisal may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Diflunisal is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Diflunisal.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Diflunisal.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Feprazone.Experimental
Ferulic acidDiflunisal may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Diflunisal.Approved
FleroxacinDiflunisal may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Diflunisal.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fludrocortisone.Approved
FluindioneDiflunisal may increase the anticoagulant activities of Fluindione.Investigational
FlumequineDiflunisal may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Diflunisal.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Diflunisal.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Diflunisal.Approved, Nutraceutical, Vet Approved
FondaparinuxDiflunisal may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumDiflunisal may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Diflunisal.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilDiflunisal may decrease the antihypertensive activities of Fosinopril.Approved
FramycetinDiflunisal may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideDiflunisal may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateDiflunisal may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinDiflunisal may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinDiflunisal may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Diflunisal.Approved, Withdrawn
GemifloxacinDiflunisal may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinDiflunisal may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinDiflunisal may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ADiflunisal may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Diflunisal.Approved, Nutraceutical
GliclazideDiflunisal may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideDiflunisal may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideDiflunisal may increase the hypoglycemic activities of Glipizide.Approved
GlyburideDiflunisal may increase the hypoglycemic activities of Glyburide.Approved
GPX-150Diflunisal may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinDiflunisal may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Diflunisal is combined with HE3286.Investigational
Hemoglobin crosfumarilDiflunisal may increase the anticoagulant activities of Hemoglobin crosfumaril.Experimental
HeparinDiflunisal may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diflunisal.Approved, Investigational
HydralazineDiflunisal may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diflunisal.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Diflunisal.Approved
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Diflunisal.Investigational
Hygromycin BDiflunisal may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibandronate.Approved, Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Diflunisal.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Diflunisal is combined with Icatibant.Approved
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Diflunisal.Approved, Nutraceutical
IdarubicinDiflunisal may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxDiflunisal may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Diflunisal.Approved, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Diflunisal.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Diflunisal.Approved, Investigational
ImidaprilDiflunisal may decrease the antihypertensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Diflunisal.Approved
IndenololDiflunisal may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Diflunisal.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Indoprofen.Withdrawn
INNO-206Diflunisal may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
Insulin AspartDiflunisal may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirDiflunisal may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineDiflunisal may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineDiflunisal may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanDiflunisal may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproDiflunisal may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Diflunisal.Approved, Investigational
IsepamicinDiflunisal may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Diflunisal is combined with Istaroxime.Investigational
KanamycinDiflunisal may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Kebuzone.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Diflunisal.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Diflunisal.Approved
LabetalolDiflunisal may decrease the antihypertensive activities of Labetalol.Approved
LandiololDiflunisal may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Diflunisal.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Diflunisal.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Leflunomide.Approved, Investigational
LepirudinDiflunisal may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanDiflunisal may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololDiflunisal may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinDiflunisal may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Diflunisal.Approved
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Diflunisal.Experimental
LiraglutideDiflunisal may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilDiflunisal may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Diflunisal.Approved
LonazolacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Diflunisal.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Diflunisal.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Diflunisal.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Diflunisal.Approved
ME-609The risk or severity of adverse effects can be increased when Diflunisal is combined with ME-609.Investigational
MecaserminDiflunisal may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Diflunisal.Approved
MelagatranDiflunisal may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Diflunisal.Approved, Vet Approved
MepindololDiflunisal may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineDiflunisal may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Diflunisal is combined with Metamizole.Withdrawn
MetforminDiflunisal may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Diflunisal.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diflunisal.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Methylprednisolone.Approved, Vet Approved
MetipranololDiflunisal may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Diflunisal.Approved
MetoprololDiflunisal may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideDiflunisal may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinDiflunisal may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifepristoneDiflunisal may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolDiflunisal may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Diflunisal.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Diflunisal.Approved
MizoribineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mizoribine.Investigational
MoexiprilDiflunisal may decrease the antihypertensive activities of Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Diflunisal.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Diflunisal.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mycophenolic acid.Approved
NadololDiflunisal may decrease the antihypertensive activities of Nadolol.Approved
NadroparinDiflunisal may increase the anticoagulant activities of Nadroparin.Approved
NafamostatDiflunisal may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Diflunisal.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Diflunisal.Investigational
Nalidixic AcidDiflunisal may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Diflunisal.Approved, Vet Approved
NateglinideDiflunisal may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Diflunisal is combined with NCX 1022.Investigational
NeamineDiflunisal may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinDiflunisal may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinDiflunisal may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Nepafenac.Approved
NetilmicinDiflunisal may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Diflunisal.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Diflunisal.Investigational
NorfloxacinDiflunisal may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diflunisal.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Diflunisal.Approved
OlsalazineDiflunisal may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatDiflunisal may decrease the antihypertensive activities of Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Orgotein.Vet Approved
OtamixabanDiflunisal may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oxaprozin.Approved
Oxolinic acidDiflunisal may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololDiflunisal may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oxyphenbutazone.Withdrawn
OzagrelThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ozagrel.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Paramethasone.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Parnaparin.Approved
ParomomycinDiflunisal may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Parthenolide.Investigational
PazufloxacinDiflunisal may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinDiflunisal may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololDiflunisal may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineDiflunisal may increase the hypoglycemic activities of Pentamidine.Approved
Pentosan PolysulfateDiflunisal may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Diflunisal.Approved, Investigational
PerindoprilDiflunisal may decrease the antihypertensive activities of Perindopril.Approved
PhenindioneDiflunisal may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonDiflunisal may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Diflunisal.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Diflunisal.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Diflunisal.Approved, Investigational
PindololDiflunisal may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneDiflunisal may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
Pipemidic acidDiflunisal may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinDiflunisal may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideDiflunisal may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pirfenidone.Investigational
Piromidic acidDiflunisal may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Diflunisal.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pirprofen.Experimental
PlazomicinDiflunisal may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinDiflunisal may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Diflunisal.Approved
PractololDiflunisal may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Diflunisal.Approved
PramlintideDiflunisal may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pranoprofen.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Diflunisal.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pregnenolone.Experimental
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Diflunisal.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Propacetamol.Approved
PropranololDiflunisal may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Diflunisal.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Diflunisal.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Diflunisal.Vet Approved
Protein CDiflunisal may increase the anticoagulant activities of Protein C.Approved
Protein S humanDiflunisal may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDiflunisal may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinDiflunisal may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Diflunisal is combined with PTC299.Investigational
PuromycinDiflunisal may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilDiflunisal may decrease the antihypertensive activities of Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Diflunisal.Approved
QuinineDiflunisal may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Diflunisal.Investigational
RamiprilDiflunisal may decrease the antihypertensive activities of Ramipril.Approved
RepaglinideDiflunisal may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineDiflunisal may decrease the antihypertensive activities of Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Diflunisal.Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Reteplase.Approved
ReviparinDiflunisal may increase the anticoagulant activities of Reviparin.Approved
RibostamycinDiflunisal may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Diflunisal.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Risedronate.Approved, Investigational
RivaroxabanDiflunisal may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Rosiglitazone.Approved, Investigational
RosoxacinDiflunisal may increase the neuroexcitatory activities of Rosoxacin.Approved
RufloxacinDiflunisal may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinDiflunisal may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Diflunisal.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Diflunisal.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Diflunisal.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Diflunisal.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Saruplase.Experimental
SaxagliptinDiflunisal may increase the hypoglycemic activities of Saxagliptin.Approved
SelexipagThe risk or severity of adverse effects can be increased when Diflunisal is combined with Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Diflunisal is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Diflunisal is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Diflunisal.Approved, Vet Approved
SisomicinDiflunisal may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinDiflunisal may increase the neuroexcitatory activities of Sitafloxacin.Experimental
SitagliptinDiflunisal may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Diflunisal.Approved
SotalolDiflunisal may decrease the antihypertensive activities of Sotalol.Approved
SP1049CDiflunisal may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinDiflunisal may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinDiflunisal may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilDiflunisal may decrease the antihypertensive activities of Spirapril.Approved
SpironolactoneDiflunisal may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Diflunisal.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Streptokinase.Approved
StreptomycinDiflunisal may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinDiflunisal may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineDiflunisal may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleDiflunisal may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Diflunisal.Approved
SulfisoxazoleDiflunisal may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Diflunisal.Approved
SulodexideDiflunisal may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Diflunisal.Investigational
SunitinibDiflunisal may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Suxibuzone.Experimental
TacrolimusDiflunisal may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Diflunisal.Approved
TalinololDiflunisal may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Diflunisal.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Diflunisal.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diflunisal.Approved, Investigational
TemafloxacinDiflunisal may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilDiflunisal may decrease the antihypertensive activities of Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Diflunisal.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Teriflunomide.Approved
TertatololDiflunisal may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Diflunisal.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tiaprofenic acid.Approved
TicagrelorThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Diflunisal.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tiludronic acid.Approved, Vet Approved
TimololDiflunisal may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tinzaparin.Approved
TioclomarolDiflunisal may increase the anticoagulant activities of Tioclomarol.Experimental
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Diflunisal.Approved
TixocortolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tixocortol.Approved
TobramycinDiflunisal may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazamideDiflunisal may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideDiflunisal may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Diflunisal.Approved
TorasemideDiflunisal may decrease the diuretic activities of Torasemide.Approved
TrandolaprilDiflunisal may decrease the antihypertensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Diflunisal.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Diflunisal.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Diflunisal.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Diflunisal.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Triamcinolone.Approved, Vet Approved
TriamtereneDiflunisal may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Diflunisal.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Diflunisal.Approved
TriptolideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Triptolide.Investigational
TrovafloxacinDiflunisal may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TroxerutinDiflunisal may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Diflunisal.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Diflunisal.Approved, Investigational
ValrubicinDiflunisal may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Diflunisal.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Diflunisal.Approved
VerapamilVerapamil may increase the anticoagulant activities of Diflunisal.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Diflunisal.Approved
WarfarinDiflunisal may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDiflunisal may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Diflunisal.Approved, Investigational, Withdrawn
ZofenoprilDiflunisal may decrease the antihypertensive activities of Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinDiflunisal may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinDiflunisal may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Avoid alcohol.
  • Food slightly delays rate of absorption with no effect on extent of absorption.
  • Take with food to reduce gastric irritation.

References

Synthesis Reference

Ruyle, W.V., Jarett, L.H. and Matzuk, A.R. ; U S . Patent 3,714,226; January 30, 1973; assigned to Merck & Co., Inc.

General References
Not Available
External Links
Human Metabolome Database
HMDB14999
KEGG Drug
D00130
KEGG Compound
C01691
PubChem Compound
3059
PubChem Substance
46507807
ChemSpider
2951
BindingDB
50240510
ChEBI
39669
ChEMBL
CHEMBL898
Therapeutic Targets Database
DAP000152
PharmGKB
PA449313
HET
1FL
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Diflunisal
ATC Codes
N02BA11 — Diflunisal
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
PDB Entries
2bxe / 3d2t / 4i89 / 5g48
FDA label
Download (94.1 KB)
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentType 2 Diabetes Mellitus1
2, 3CompletedTreatmentAmyloidosis, Familial / Familial Amyloid Polyneuropathy (FAP)1
4SuspendedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedNot AvailableAmyloidosis1

Pharmacoeconomics

Manufacturers
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Merck and co inc
Packagers
Dosage forms
FormRouteStrength
TabletOral250 mg
TabletOral500 mg/1
TabletOral500 mg
Tablet, film coatedOral500 mg/1
Prices
Unit descriptionCostUnit
Dolobid 60 500 mg tablet Bottle92.83USD bottle
Diflunisal 250 mg tablet1.74USD tablet
Diflunisal powder1.56USD g
Diflunisal 500 mg tablet1.46USD tablet
Apo-Diflunisal 500 mg Tablet0.75USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)210-211Ruyle, W.V., Jarett, L.H. and Matzuk, A.R. ; U S . Patent 3,714,226; January 30, 1973; assigned to Merck & Co., Inc.
water solubilityPractically insoluble (14.5 mg/L) at neutral or acidic pH.Not Available
logP4.44SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0711 mg/mLALOGPS
logP3.11ALOGPS
logP3.91ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)2.69ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity60.86 m3·mol-1ChemAxon
Polarizability22.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9945
Blood Brain Barrier+0.8047
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.6927
P-glycoprotein inhibitor INon-inhibitor0.9407
P-glycoprotein inhibitor IINon-inhibitor0.9735
Renal organic cation transporterNon-inhibitor0.911
CYP450 2C9 substrateNon-substrate0.7982
CYP450 2D6 substrateNon-substrate0.9201
CYP450 3A4 substrateNon-substrate0.7145
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.6684
CYP450 2D6 inhibitorNon-inhibitor0.9357
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5156
Ames testNon AMES toxic0.9666
CarcinogenicityNon-carcinogens0.7828
BiodegradationNot ready biodegradable0.988
Rat acute toxicity2.7735 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.983
hERG inhibition (predictor II)Non-inhibitor0.9178
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0fai-1690000000-d231ff5a9ac7d9769d2d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0002-2690000000-64056c9dc4e2f14d3c59
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4j-5590000000-462ea99995ea9238bf94
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4i-5490000000-ec23e03578a95364b748
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4i-9550000000-2fa065aea811fa7b6c5a
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000t-9000000000-01d2c7c75ab3756b3df7

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Salicylic acids / Benzoic acids / Benzoyl derivatives / Fluorobenzenes / 1-hydroxy-2-unsubstituted benzenoids / Aryl fluorides / Vinylogous acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organooxygen compounds
show 3 more
Substituents
Biphenyl / Hydroxybenzoic acid / Salicylic acid or derivatives / Salicylic acid / Benzoic acid or derivatives / Benzoic acid / Benzoyl / 1-hydroxy-2-unsubstituted benzenoid / Fluorobenzene / Halobenzene
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organofluorine compound, monohydroxybenzoic acid (CHEBI:39669)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Cappon GD, Cook JC, Hurtt ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003 Feb;68(1):47-56. [PubMed:12852483]
  2. Jeske AH: COX-2 inhibitors and dental pain control. J Gt Houst Dent Soc. 1999 Nov;71(4):39-40. [PubMed:10825891]
  3. Mao H, Hajduk PJ, Craig R, Bell R, Borre T, Fesik SW: Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc. 2001 Oct 31;123(43):10429-35. [PubMed:11673972]
  4. Moore PA, Hersh EV: Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6. [PubMed:11315375]
  5. Young JM, Panah S, Satchawatcharaphong C, Cheung PS: Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res. 1996 May;45(5):246-53. [PubMed:8737748]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Cappon GD, Cook JC, Hurtt ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003 Feb;68(1):47-56. [PubMed:12852483]
  2. Chen QH, Rao PN, Knaus EE: Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem. 2005 Apr 1;13(7):2459-68. [PubMed:15755648]
  3. Young JM, Panah S, Satchawatcharaphong C, Cheung PS: Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res. 1996 May;45(5):246-53. [PubMed:8737748]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A8
Uniprot ID
Q9HAW9
Uniprot Name
UDP-glucuronosyltransferase 1-8
Molecular Weight
59741.035 Da
References
  1. Cheng Z, Radominska-Pandya A, Tephly TR: Studies on the substrate specificity of human intestinal UDP- lucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos. 1999 Oct;27(10):1165-70. [PubMed:10497143]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name
TTR
Uniprot ID
P02766
Uniprot Name
Transthyretin
Molecular Weight
15886.88 Da
References
  1. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW: Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem. 2004 Jan 15;47(2):355-74. [PubMed:14711308]
  2. Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, Arsequell G, Planas A, Saraiva MJ: Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J. 2004 Jul 15;381(Pt 2):351-6. [PubMed:15080795]
  3. Gales L, Macedo-Ribeiro S, Arsequell G, Valencia G, Saraiva MJ, Damas AM: Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor. Biochem J. 2005 Jun 1;388(Pt 2):615-21. [PubMed:15689188]
  4. Miller SR, Sekijima Y, Kelly JW: Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004 May;84(5):545-52. [PubMed:14968122]
  5. Tojo K, Sekijima Y, Kelly JW, Ikeda S: Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res. 2006 Dec;56(4):441-9. Epub 2006 Oct 6. [PubMed:17028027]
Details
2. Serum albumin
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Davilas A, Koupparis M, Macheras P, Valsami G: In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique. J Pharm Pharmacol. 2006 Nov;58(11):1467-74. [PubMed:17132209]
  2. Mao H, Hajduk PJ, Craig R, Bell R, Borre T, Fesik SW: Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc. 2001 Oct 31;123(43):10429-35. [PubMed:11673972]
  3. Rehse K, Fiedler B: [Determination of the protein binding of drugs by continuous ultrafiltration. 9. Comparison of the binding of nonsteroid antirheumatics to human serum albumin and their interaction with phenprocoumon]. Arch Pharm (Weinheim). 1989 Apr;322(4):241-3. [PubMed:2751413]
  4. Verbeeck RK, De Schepper PJ: Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding. Clin Pharmacol Ther. 1980 May;27(5):628-35. [PubMed:7371361]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
  2. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13